|
Assessing the Quality of Life in Imatinib-Treated Chronic Myeloid Leukemia Patients: A Cross Sectional Descriptive Study
|
|
| Author:
|
, ABEER ABDULHADI RASHID, ZAHRAA ALBASRY
|
| Abstract:
|
Background: Chronic myeloid leukemia (CML) is a myeloproliferative malignancy characterized by Philadelphia chromosome (Ph), it represent about 20% of all leukemias and has an incidence of 1.0–1.5 per 100,000. Lately, there was a great focus on quality of life and bypassing long-term organ toxicities and, especially, by finding strategies to reach treatment free remission (TFR).
Method: Quality of life was evaluated at the diagnosis (A1), after three months (A2), and after twelve months of treatment (A3) using a questionnaires: EORTC QLQ-C30 and CML-24. All patients were treated with imatinib. The study was conducted in outpatient clinic, ward of Hematology and Department of Chemotherapy in Baghdad teaching hospital.
Results: Results for patients with CML show significant changes in both Emotional functioning and Global QL from the diagnosis until 12 months of treatment by using EORTC QLQ-C30.While Significant changes were present in Symptom burden, Impact on worry/mood, Impact on daily life, Body image problems, Satisfaction with care and information and Satisfaction with social life during period of treatment with Imatinib by using EORTC QLQ-CML24.
Conclusion: significant improvement in different aspects of quality of life using EORTC QLQ-C30 and CML-24 questionnaires were shown after treatment with Imatinib comparing with these findings before Imatinib.
|
| Keyword:
|
quality of life, chronic myeloid leukemia, Imatinib
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP2.332
|
| Download:
|
Request For Article
|
|
|